MarketPulse

Keytruda

2 articles
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Lilly's Valuation Trap vs. Merck's Dividend Appeal: A Tale of Two Pharma Giants

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.
MRKLLYvaluationdividend stocks
BenzingaBenzinga··Vandana Singh

Merck Restructures Commercial Operations Ahead of Keytruda Patent Cliff

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.
MRKrestructuringpatent expiration